Knight Therapeutics (TSE:GUD) Stock Price Up 1.6% - Here's What Happened

Key Points

• Knight Therapeutics' share price increased by 1.6%, reaching a last trading price of C$6.27 with significant trading volume, up 180% from the average.
• Canaccord Genuity Group set a price target of C$6.50 for the stock, with two analysts rating it as a "buy" and two as a "strong buy," indicating strong confidence in its potential.
• The company has a market capitalization of C$634.21 million and a negative P/E ratio of -20.93, highlighting its current financial performance challenges.

Knight Therapeutics Inc. (TSE:GUD - Get Free Report)'s share price shot up 1.6% during mid-day trading on Tuesday . The stock traded as high as C$6.31 and last traded at C$6.27. 181,254 shares traded hands during mid-day trading, an increase of 180% from the average session volume of 64,832 shares. The stock had previously closed at C$6.17.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group set a C$6.50 price target on Knight Therapeutics and gave the stock a "buy" rating in a report on Friday, May 9th. Two analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Strong Buy" and a consensus price target of C$7.15.

Knight Therapeutics Stock Up 1.6%

The firm has a fifty day simple moving average of C$5.99 and a 200-day simple moving average of C$5.86. The company has a market capitalization of C$634.21 million, a P/E ratio of -20.93, a P/E/G ratio of -1,013.50 and a beta of 0.50. The company has a quick ratio of 1.79, a current ratio of 3.36 and a debt-to-equity ratio of 7.52.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.